Ozenoxacin - Ferrer/Maruho

Drug Profile

Ozenoxacin - Ferrer/Maruho

Alternative Names: GF-001001-00; M-512101; M5120; OZANEX; T-3912; Xepi

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toyama Chemical
  • Developer Cipher Pharmaceuticals; Ferrer; Maruho
  • Class Antibacterials; Cyclopropanes; Pyridines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Impetigo
  • Registered Acne vulgaris; Skin and soft tissue infections

Most Recent Events

  • 05 Mar 2018 Ozenoxacin sub-licensed to Cutanea Life Sciences from Medimetrix Pharmaceuticals in USA
  • 05 Mar 2018 Updated adverse events data from clinical trials in Impetigo released by Cutanea Life Sciences
  • 08 Jan 2018 Launched for Impetigo (In adolescents, In children, In infants, In adults) in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top